Your browser doesn't support javascript.
loading
Gaucher disease type 1: the first experience of enzyme replacement therapy in pediatric practice in Moldova - case report.
Usurelu, Natalia; Blanita, Daniela; Boiciuc, Chiril; Hlistun, Victoria; Egorov, Vladimir; Popovici, Eugen; Gnatcova, Elena; Stamati, Adela; Oglinda, Ana; Revenco, Ninel; Gladun, Sergiu; Turea, Valentin.
Affiliation
  • Usurelu N; Institute of Mother and Child, Chisinau, Republic of Moldova.
  • Blanita D; Institute of Mother and Child, Chisinau, Republic of Moldova.
  • Boiciuc C; Institute of Mother and Child, Chisinau, Republic of Moldova.
  • Hlistun V; Institute of Mother and Child, Chisinau, Republic of Moldova.
  • Egorov V; Institute of Mother and Child, Chisinau, Republic of Moldova.
  • Popovici E; Institute of Mother and Child, Chisinau, Republic of Moldova.
  • Gnatcova E; Institute of Mother and Child, Chisinau, Republic of Moldova.
  • Stamati A; "Nicolae Testemitanu" State University of Medicine and Pharmacy, Chisinau, Republic of Moldova.
  • Oglinda A; "Nicolae Testemitanu" State University of Medicine and Pharmacy, Chisinau, Republic of Moldova.
  • Revenco N; Institute of Mother and Child, Chisinau, Republic of Moldova.
  • Gladun S; "Nicolae Testemitanu" State University of Medicine and Pharmacy, Chisinau, Republic of Moldova.
  • Turea V; Institute of Mother and Child, Chisinau, Republic of Moldova.
Med Pharm Rep ; 94(Suppl No 1): S57-S60, 2021 Aug.
Article in En | MEDLINE | ID: mdl-34527913
ABSTRACT
We report on a case of a little girl patient diagnosed with Gaucher disease (GD) type 1 in her early childhood and our first experience with enzyme replacement therapy (ERT). She was first diagnosed accidentally with enlarged spleen during a pediatric examination when she was three years old, but the family ignored investigations; she was hospitalized for diagnosis at six years old. The GD was confirmed based on clinical manifestations of left abdominal flank pain, multiple bruising, general weakness, bone pain, low appetite, failure to thrive <5th percentile, minor hepato- and severe splenomegaly, enlarged submaxillary lymph nodes, associated by anemia with normal platelets; low activity of beta-Glucosidase, two found mutations in GBA gene, Gaucher cells in bone marrow. The ERT was initiated with Imiglucerase (54 UI/kg/2 wks) two years later after diagnosis, avoiding the splenectomy. Subsequently, the platelets showed the first a promising result, gradually increasing their number every 2 weeks and maintaining it in good parameters till the reported moment (2.5 yrs from the start). The hemoglobin level was appreciated within normal ranges 3 months after ERT start and stabilized completely after 6 months. On the other hand, the red blood count normalized within 20 months of applied therapy. The Lyso-GL-1 decreased by 30% after three months of therapy, no antibodies to Imiglucerase were found. The initial spleen volume (1178.19 cm3) decreased by almost 60% in 6 months of ERT, reaching absolutely normal dimensions after 9 months. The ERT with Imiglucerase was tolerated very well by the patient, showing a clear improvement of clinical symptoms after 4-6 months of therapy, hematological picture and splenomegaly solving. Even if the little patient had to come every 2 weeks for infusion, her quality of life improved a lot, being a totally happy child, going to school and having friends. The ERT should be initiated immediately after diagnosis to prevent the multisystem complications.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Aspects: Patient_preference Language: En Journal: Med Pharm Rep Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Aspects: Patient_preference Language: En Journal: Med Pharm Rep Year: 2021 Document type: Article